Type 2 Inflammation Biologic (Anti-IL-4/IL-13) from Sanofi / Regeneron.
Dupixent has one of the broadest sets of FDA-approved indications of any Type 2 biologic — covering atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, and COPD with Type 2 inflammation. By blocking the IL-4 and IL-13 pathways central to Type 2 inflammation, it can address multiple coexisting conditions with a single therapy.
Dupixent is FDA-approved for the following indications:
Dupixent now carries nine FDA-approved indications — the broadest of any Type 2 biologic. The most recent, allergic fungal rhinosinusitis, was approved February 24, 2026, and Dupixent is currently the first and only medicine approved specifically for it. Not every patient with these diagnoses is a candidate; each indication has its own criteria.
Dupixent is administered subcutaneously every two weeks via self-injection at home. Patients are trained on technique and many use auto-injector formulations for convenience.
The manufacturer offers a patient support program — Dupixent MyWay Patient Support — that can help with insurance navigation, copay assistance for eligible patients, nursing support, and ongoing education. More information is available at https://www.dupixent.com/support-savings/myway.
Treatment with Dupixent is initiated and monitored by Dr. McNeil. Prior authorizations are handled in-house — patients are not asked to navigate insurance approvals on their own. This is a subcutaneous self-administered medication. After prior authorization, the prescription is sent to a specialty pharmacy that ships the medication directly to the patient. A manufacturer-sponsored nurse or office-based training visit is typically arranged for the first dose so patients are confident with self-administration before continuing at home.
Important safety note: This page is not a substitute for the FDA prescribing information. Risks, contraindications, drug interactions, and required monitoring vary by patient. The official manufacturer website (https://www.dupixent.com) provides the most current full prescribing and safety information. Treatment decisions and monitoring are individualized — please discuss with Dr. McNeil whether Dupixent is appropriate for your situation.
Donald L. McNeil, MD · Board Certified in Allergy & Immunology and Internal Medicine
This page is provided for educational purposes only and is not medical advice. If you have an emergency, call 911.